Allurion Technologies (NYSE: ALUR) stock soared almost 80% in intraday trading Thursday amid news of the commercial launch of its VCS in the United States.
Allurion (ALUR) has announced the availability of its Virtual Care Suite (VCS) for licensing in the United States, catering specifically to providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices.
VCS is a comprehensive weight-loss management solution powered by artificial intelligence (AI), integrating features like remote patient monitoring, telehealth services, and collaborative care team tools.
According to the press release, the VCS will debut in the United States at the Obesity Medicine Conference in Denver on April 25. During the event, providers will have the opportunity to engage in one-on-one meetings to explore the capabilities of this innovative solution. In addition, Allurion will launch an updated version of Allurion Insights, the web-based dashboard integral to navigating VCS and accessing patient data and insights.
In a separate development, Chardan Capital analyst Keay Nakae has initiated coverage on ALUR stock with a Buy rating. The analyst has set a price target of $5.
Allurion (NYSE: ALUR) Stock Reaction
ALUR stock surged 78.03% to close at $3.08 on Thursday. The traders had exchanged hands with 59,132,615 (59.13 million) shares compared to the average daily trading volume of 31.61K.
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
